Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Autoimmune Disease Research
NovImmune SA files IND in the Netherlands for a human antibody that targets the CD3 antigen
February 14th, 2006
Medarex, Inc. (MEDX) announced the filing of an investigational new drug (IND) application in the Netherlands by its licensing partner, NovImmune SA, for NI-0401, a fully human antibody that targets the CD3 antigen, for the treatment of autoimmune disease. The antibody product was developed using Medarex's UltiMAb technology. Medarex expects to receive an undisclosed milestone payment and may receive future milestone payments and royalties should this product candidate progress through clinical development. Donald L. Drakeman, president and CEO of Medarex, Inc. said, "With the advancement of the NovImmune antibody into clinical trials, there are now...
Source: Cancer Weekly (2006-02-14)
|
